Pharvaris PHVS
NASDAQ PHVS
$36.14 +0.48 (+1.35%)
As of: Sep 4, 2026 · 1:34 PM EDT

Pharvaris (PHVS) Interest Expenses (2021 - 2026)

Pharvaris' (PHVS) quarterly Interest Expenses came in at -$128.4 billion in Q3 2024, up 50.04% on a QoQ basis from -$257.0 billion in Q4 2023.

Analysis

Pharvaris (PHVS) Interest Expenses (2021 - 2026) Analysis & Trends

Pharvaris (PHVS) has 5 years of Interest Expenses data on file, last reported at -$128.4 billion in Q3 2024.

  • Quarterly Interest Expenses changed N/A year-over-year to -$128.4 billion in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$128.4 billion (down 191289232.56% YoY) and the FY2023 annual result came in at -$258.4 billion, down 624644381.68% from the prior year.
  • Interest Expenses grew to -$128.4 billion in Q3 2024, from -$257.0 billion in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $297037.2 in Q2 2021 to a low of -$257.0 billion in Q4 2023.
  • A 5-year average of -$32.1 billion and a median of $6801.0 in 2022 frame the typical range for Interest Expenses.
  • Annual changes were most pronounced in 2021 — Interest Expenses soared 535.92% — and 2023, when it plunged 382873551.54%.
  • Tracing PHVS's Interest Expenses over 5 years: stood at $46709.6 in 2020, then slipped by 28.12% to $33574.4 in 2021, then slumped by 299.96% to -$67136.4 in 2022, then sank by 382873551.54% to -$257.0 billion in 2023, then soared by 50.04% to -$128.4 billion in 2024.
  • The last three Interest Expenses figures came in at -$128.4 billion (Q3 2024), -$257.0 billion (Q4 2023), and -$67136.4 (Q4 2022), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Vertex Pharmaceuticals 139.27 Bn 131.42 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.45 Bn 58.27 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.73 Bn 52.59 Bn 52.00 Mn -
5 Revolution Medicines 44.08 Bn 44.08 Bn - 23.78 Mn
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.14 Bn 31.84 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 93.62 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 20.27 Mn
10 Pharvaris 2.13 Bn 1.76 Bn 85,072.10 4.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.12 Mn
Mar 31, 2026 6.26 Mn
Dec 31, 2025 -1.23 Mn
Sep 30, 2025 6.93 Mn
Jun 30, 2025 -5.55 Mn
Mar 31, 2025 -4.05 Mn
Dec 31, 2024 12.36 Mn
Sep 30, 2024 -3.93 Mn
Jun 30, 2024 5,084.58 Bn
Mar 31, 2024 2.25 Mn
Dec 31, 2023 -3,133.83 Bn
Sep 30, 2023 2.99 Mn
Jun 30, 2023 709.62 Bn
Mar 31, 2023 -1.60 Mn
Dec 31, 2022 -90,754.06
Sep 30, 2022 11.59 Mn
Jun 30, 2022 12,273.08 Bn
Mar 31, 2022 3.81 Mn
Jun 30, 2021 -2.98 Mn
Mar 31, 2021 7.02 Mn